Mod GRF 1-29 & GHRP-6 Blend (10mg)

Description

Mod GRF 1-29 & GHRP-6 Peptide Blend — Research Overview

Mod GRF 1-29 & GHRP-6 Peptide Blend is a synergistic research combination designed to investigate the dual stimulation of growth hormone (GH) secretion via both GHRH and ghrelin receptor pathways. This blend combines two potent synthetic peptides — Modified GRF 1-29 (CJC-1295 without DAC) and GHRP-6 (Growth Hormone Releasing Peptide-6) — each known for their distinct but complementary mechanisms of action.

Both compounds have been extensively researched for their potential to stimulate pituitary GH release, enhance IGF-1 levels, and promote anabolic processes, offering valuable insights into endocrinology, muscle metabolism, and age-related hormone decline.

---

Chemical Composition

Mod GRF 1-29

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

• Molecular Weight: 3367.95 g/mol

• Other Names: CJC-1295 without DAC, tetrasubstituted GRF (1-29)

GHRP-6

• Molecular Formula: C₄₆H₅₆N₁₂O₆

• Molecular Weight: 873.03 g/mol

• Other Names: Growth Hormone Releasing Peptide-6

---

Mechanism of Action

1. Mod GRF 1-29 (CJC-1295 without DAC)

Mod GRF 1-29 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), designed to mimic its natural action on the anterior pituitary gland. By binding to GHRH receptors on somatotroph cells, it triggers the adenylyl cyclase–cAMP–PKA signaling cascade, which may lead to increased calcium influx and subsequent GH secretion.

This mechanism may also support the upregulation of insulin-like growth factor-1 (IGF-1), a key mediator in tissue growth, repair, and metabolism.

2. GHRP-6

GHRP-6 is a ghrelin mimetic that activates Growth Hormone Secretagogue Receptor (GHS-R1a). Upon activation, it may stimulate phospholipase C (PLC) and inositol trisphosphate (IP3) pathways, increasing intracellular calcium levels — another potent trigger for GH release.

Additionally, GHRP-6 may influence appetite regulation, energy expenditure, and recovery processes, making it a vital tool for exploring metabolic and anabolic functions.

---

Potential Synergistic Effects

When combined, Mod GRF 1-29 and GHRP-6 appear to produce a synergistic enhancement of GH secretion, as they act through distinct receptor pathways. This dual stimulation may result in greater pulsatile GH release compared to the effects observed when each peptide is used independently.

Research suggests that this combination may lead to significant increases in IGF-1 levels, lean muscle mass, and metabolic activity, potentially exceeding the efficacy of individual peptides.

---

Research Applications

Studies indicate potential uses of the Mod GRF 1-29 & GHRP-6 blend in various experimental contexts, including:

• Growth Hormone Deficiency (GHD): Investigation into restoring physiological GH secretion and linear growth enhancement.

• Muscle Wasting and Cachexia: Exploring the anti-catabolic and anabolic potential in degenerative or muscle-wasting conditions.

• Aging and Longevity Research: Examining the effects of increased GH/IGF-1 on age-related decline in tissue repair and vitality.

• Metabolic Regulation: Evaluating their influence on lipid metabolism, insulin sensitivity, and energy utilization.

---

Safety and Observations

Commonly reported effects in experimental models include transient flushing, increased appetite, and mild water retention—all consistent with GH secretagogue activity. Both peptides appear to demonstrate high receptor selectivity and favorable tolerability profiles in preclinical studies.

This product is intended strictly for laboratory research use only. It is not approved for human consumption, medical use, or therapeutic applications.

---

References

1. Cabrales, A. et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine healthy male volunteers. Eur J Pharm Sci. 2013;48(1–2):40–46.

2. Sinha, D. K. et al. Role of Growth Hormone Secretagogues in body composition management. Transl Androl Urol. 2020;9(Suppl 2):S149–S159.

3. Abizaid, A., & Hougland, J. L. Ghrelin Signaling: GOAT and GHS-R1a Take a LEAP in Complexity. Trends Endocrinol Metab. 2020;31(2):107–117.

4. Sigalos, J. T. et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises IGF-1 Levels. Am J Mens Health. 2017;11(6):1752–1757.